Perimidine is a heterocyclic compound containing a pyrimidine ring fused to a benzene ring. It is a nitrogen-containing aromatic ring system that can be synthesized through various methods, including the condensation of o-phenylenediamine with a β-ketoester. Perimidines exhibit diverse biological activities, such as antibacterial, antifungal, and antitumor effects. They have been explored for their potential as therapeutic agents due to their ability to interact with various biological targets, including DNA, enzymes, and receptors. The study of perimidines is driven by their intriguing chemical properties, their potential for medicinal applications, and their potential role in the development of novel drug candidates.'
| ID Source | ID |
|---|---|
| PubMed CID | 120189 |
| CHEMBL ID | 3717833 |
| CHEBI ID | 36426 |
| SCHEMBL ID | 8112 |
| MeSH ID | M0077657 |
| Synonym |
|---|
| 204-02-4 |
| CHEBI:36426 |
| 1h-benzo(de)quinazoline |
| perimidine |
| 1h-perimidine |
| AE-848/00905041 |
| brn 0129318 |
| STK394055 |
| AKOS000296733 |
| 5-23-08-00212 (beilstein handbook reference) |
| peri-naphthimidazole |
| SCHEMBL8112 |
| AAQTWLBJPNLKHT-UHFFFAOYSA-N |
| DTXSID70174343 |
| CHEMBL3717833 |
| Q27116826 |
| Class | Description |
|---|---|
| perimidine | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| G protein-coupled receptor kinase 6 | Homo sapiens (human) | IC50 (µMol) | 12.5400 | 0.0329 | 3.1789 | 8.7000 | AID1259606 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| G protein-coupled receptor signaling pathway | G protein-coupled receptor kinase 6 | Homo sapiens (human) |
| regulation of G protein-coupled receptor signaling pathway | G protein-coupled receptor kinase 6 | Homo sapiens (human) |
| Wnt signaling pathway | G protein-coupled receptor kinase 6 | Homo sapiens (human) |
| regulation of signal transduction | G protein-coupled receptor kinase 6 | Homo sapiens (human) |
| protein phosphorylation | G protein-coupled receptor kinase 6 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| protein binding | G protein-coupled receptor kinase 6 | Homo sapiens (human) |
| ATP binding | G protein-coupled receptor kinase 6 | Homo sapiens (human) |
| beta-adrenergic receptor kinase activity | G protein-coupled receptor kinase 6 | Homo sapiens (human) |
| G protein-coupled receptor kinase activity | G protein-coupled receptor kinase 6 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| plasma membrane | G protein-coupled receptor kinase 6 | Homo sapiens (human) |
| membrane | G protein-coupled receptor kinase 6 | Homo sapiens (human) |
| cytoplasm | G protein-coupled receptor kinase 6 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (5.88) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (23.53) | 29.6817 |
| 2010's | 10 (58.82) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (30.18) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (5.56%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 17 (94.44%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||